These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8648772)

  • 21. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors affecting progression and survival in metastatic prostate cancer.
    Nayyar R; Sharma N; Gupta NP
    Urol Int; 2010; 84(2):159-63. PubMed ID: 20215819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum alkaline phosphatase predicts survival outcomes in patients with skeletal metastatic nasopharyngeal carcinoma.
    Jin Y; Yuan MQ; Chen JQ; Zhang YP
    Clinics (Sao Paulo); 2015 Apr; 70(4):264-72. PubMed ID: 26017793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
    Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
    Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.
    Anvari K; Seilanian Toussi M; Kalantari M; Naseri S; Karimi Shahri M; Ahmadnia H; Katebi M; Sedighi Pashaki A; Dayani M; Broumand M
    Urol J; 2012; 9(1):381-8. PubMed ID: 22395836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate.
    Rana A; Chisholm GD; Khan M; Rashwan HM; Elton RA
    Br J Urol; 1994 Nov; 74(5):637-41. PubMed ID: 7827816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of surgical and radiotherapy of prostatic cancer T1-4N0-1M0].
    Matveev VB; Tkachev SI; Volkova MI; Mitin AA; Kalinin SA; Shelepova VM
    Urologiia; 2009; (3):33-9. PubMed ID: 19670814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
    Sasaki T; Onishi T; Hoshina A
    Endocr Relat Cancer; 2012 Oct; 19(5):725-30. PubMed ID: 22807499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical prostatectomy and prognostic factors.
    du Fossé W; Billiet I; Mattelaer J
    Acta Urol Belg; 1997 Oct; 65(3):53-62. PubMed ID: 9421937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
    Zhang XZ; Donovan MP; Williams BT; Mohler JL
    Urology; 1996 Mar; 47(3):402-4. PubMed ID: 8633409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.